

Michael Mian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8396994/publications.pdf>

Version: 2024-02-01

84
papers

1,781
citations

236612

25
h-index

301761

39
g-index

85
all docs

85
docs citations

85
times ranked

3001
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study). <i>Hematological Oncology</i> , 2022, 40, 609-616. | 0.8 | 0 |
| 2 | Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44. | 2.2 | 29 |
| 3 | Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609. | 1.3 | 3 |
| 4 | STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma. <i>Hematological Oncology</i> , 2020, 38, 106-110. | 0.8 | 9 |
| 5 | ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. <i>American Journal of Hematology</i> , 2020, 95, 1030-1037. | 2.0 | 6 |
| 6 | The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. <i>Journal of Clinical Medicine</i> , 2020, 9, 1005. | 1.0 | 3 |
| 7 | Primary central nervous system lymphoma: Novel precision therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 139-145. | 2.0 | 9 |
| 8 | Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e489-e495. | 0.2 | 7 |
| 9 | Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP. <i>Hematological Oncology</i> , 2019, 37, 333-344. | 0.8 | 38 |
| 10 | Phase III trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. <i>British Journal of Haematology</i> , 2019, 185, 944-947. | 1.2 | 5 |
| 11 | Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460. | 1.9 | 22 |
| 12 | Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. <i>Oncotarget</i> , 2017, 8, 20394-20409. | 0.8 | 30 |
| 13 | Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016, 95, 1107-1114. | 0.8 | 25 |
| 14 | Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?. <i>Oncologist</i> , 2016, 21, 1107-1112. | 1.9 | 33 |
| 15 | Quality of life in patients with invasive bladder cancer who cannot undergo cystectomy. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 339-345. | 0.6 | 1 |
| 16 | 90Y-ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 82-88. | 0.2 | 6 |
| 17 | 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. <i>Oncotarget</i> , 2016, 7, 7597-7609. | 0.8 | 31 |
| 18 | Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?. <i>Anticancer Research</i> , 2016, 36, 1059-65. | 0.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. <i>Experimental Hematology and Oncology</i> , 2015, 5, 1. | 2.0 | 6 |
| 20 | Cancer Cachexia Syndrome: Pathogenesis, Diagnosis, and New Therapeutic Options. <i>Nutrition and Cancer</i> , 2015, 67, 12-26. | 0.9 | 53 |
| 21 | Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?. <i>Acta Oncologica</i> , 2015, 54, 953-955. | 0.8 | 3 |
| 22 | Changing treatment paradigms in lymphoma: new targets and new drugs. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 184-188. | 0.3 | 0 |
| 23 | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153. | 1.9 | 52 |
| 24 | B Cell Lymphoma with Lung Involvement: What Is It about?. <i>Acta Haematologica</i> , 2015, 133, 221-225. | 0.7 | 11 |
| 25 | Comparison of Complications from Radical Cystectomy between Old-Old versus Oldest-Old Patients. <i>Urologia Internationalis</i> , 2015, 94, 25-30. | 0.6 | 25 |
| 26 | High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3903-3910. | 0.8 | 99 |
| 27 | Cardiovascular Comorbidities and Events in NSCLC: Often Underestimated but Worth Considering. <i>Clinical Lung Cancer</i> , 2015, 16, 305-312. | 1.1 | 17 |
| 28 | Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. <i>Annals of Hematology</i> , 2015, 94, 593-601. | 0.8 | 6 |
| 29 | Pim kinases in hematological malignancies: where are we now and where are we going?. <i>Journal of Hematology and Oncology</i> , 2014, 7, 95. | 6.9 | 72 |
| 30 | Rituximab: how evidence based medicine can change our clinical practice. <i>Leukemia and Lymphoma</i> , 2014, 55, 1694-1696. | 0.6 | 0 |
| 31 | Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18-year follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , 2014, 93, 221-231. | 0.8 | 36 |
| 32 | Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. <i>Annals of Hematology</i> , 2014, 93, 267-277. | 0.8 | 17 |
| 33 | Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer. <i>World Journal of Urology</i> , 2014, 32, 1219-1223. | 1.2 | 30 |
| 34 | Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014, 164, 896-899. | 1.2 | 0 |
| 35 | Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. <i>SpringerPlus</i> , 2014, 3, 342. | 1.2 | 3 |
| 36 | Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. <i>SpringerPlus</i> , 2014, 3, 123. | 1.2 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | R-CHOP versus R-COMP: Are They Really Equally Effective?. <i>Clinical Oncology</i> , 2014, 26, 648-652. | 0.6 | 12 |
| 38 | A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. <i>Anticancer Research</i> , 2014, 34, 2559-64. | 0.5 | 6 |
| 39 | 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. <i>Anticancer Research</i> , 2014, 34, 5121-5. | 0.5 | 6 |
| 40 | Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal?. <i>Anticancer Research</i> , 2014, 34, 6701-4. | 0.5 | 10 |
| 41 | â€œIdiopathic Bence-Jones proteinuriaâ€: a new characterization of an old entity. <i>Annals of Hematology</i> , 2013, 92, 1263-1270. | 0.8 | 7 |
| 42 | Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. <i>World Journal of Urology</i> , 2013, 31, 293-297. | 1.2 | 1 |
| 43 | Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , 2013, 24, 1378-1384. | 0.6 | 13 |
| 44 | Bendamustine salvage for the treatment of relapsed Hodgkinâ€™s lymphoma after allogeneic bone marrow transplantation. <i>Annals of Hematology</i> , 2013, 92, 121-123. | 0.8 | 9 |
| 45 | Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68. | 0.6 | 14 |
| 46 | Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. <i>American Journal of Hematology</i> , 2013, 88, 955-960. | 2.0 | 14 |
| 47 | Docetaxel in the treatment of non-small cell lung cancer (NSCLC) – an observational study focusing on symptom improvement. <i>Anticancer Research</i> , 2013, 33, 3831-6. | 0.5 | 10 |
| 48 | Osteolytic bone lesions as a rare sign of progression of chronic lymphocytic leukemia without evidence of Richter syndrome. <i>Leukemia and Lymphoma</i> , 2012, 53, 993-995. | 0.6 | 8 |
| 49 | Authors' response to Professor J. F. Seymour. <i>Leukemia and Lymphoma</i> , 2012, 53, 1012-1012. | 0.6 | 0 |
| 50 | Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012, 23, 729-735. | 0.6 | 19 |
| 51 | Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012, 30, 46-49. | 0.8 | 20 |
| 52 | High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832. | 0.6 | 23 |
| 53 | Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604. | 0.6 | 173 |
| 54 | Single- vs. Two-Stage Fowler-Stephens Orchidopexy: Are Two Operations Better than One? A Retrospective, Single-Institution Critical Analysis. <i>Current Urology</i> , 2011, 5, 12-17. | 0.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011, 153, 499-503. | 1.2 | 12 |
| 56 | Gains of <i>MYC</i> locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2011, 155, 274-277. | 1.2 | 47 |
| 57 | Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599. | 1.2 | 40 |
| 58 | CLIP: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408. | 0.8 | 28 |
| 59 | Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011, 29, 38-41. | 0.8 | 29 |
| 60 | Fluorescence In Situ Hybridisation in the Diagnosis of Upper Urinary Tract Tumours. <i>European Urology</i> , 2010, 58, 288-292. | 0.9 | 68 |
| 61 | Genomic profiling of Richter's syndrome: recurrent lesions and differences with <i>de novo</i> diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , 2010, 28, 62-67. | 0.8 | 46 |
| 62 | Syk expression patterns differ among B-cell lymphomas. <i>Leukemia Research</i> , 2010, 34, e243-e245. | 0.4 | 3 |
| 63 | Genome wide DNA-profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , 2010, 148, 245-255. | 1.2 | 70 |
| 64 | Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 149, 569-577. | 1.2 | 53 |
| 65 | Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , 2010, 151, 221-231. | 1.2 | 47 |
| 66 | Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439. | 1.2 | 20 |
| 67 | Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells. <i>Pathobiology</i> , 2010, 77, 129-135. | 1.9 | 26 |
| 68 | Patterns of survival of follicular lymphomas at a single institution through three decades. <i>Leukemia and Lymphoma</i> , 2010, 51, 1028-1034. | 0.6 | 33 |
| 69 | SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010, 116, 3611-3611. | 0.6 | 4 |
| 70 | Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. <i>Blood</i> , 2010, 116, 1784-1784. | 0.6 | 1 |
| 71 | Comparison of Complications in Three Incontinent Urinary Diversions. <i>European Urology</i> , 2008, 54, 825-834. | 0.9 | 73 |
| 72 | The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). <i>Blood</i> , 2008, 112, 3608-3608. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2007, 110, 1282-1282. | 0.6 | 3 |
| 74 | 240: Is Fish on Voided Urine a Predictive Marker for the Response to Farmorubicin Intravesical Instillation in Intermediate Risk Bladder Cancer?. <i>Journal of Urology</i> , 2007, 177, 80-80. | 0.2 | 0 |
| 75 | Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 3432-3432. | 0.6 | 0 |
| 76 | Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra. <i>Leukemia and Lymphoma</i> , 2006, 47, 940-943. | 0.6 | 4 |
| 77 | Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1683-1685. | 0.6 | 29 |
| 78 | Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7. <i>Prostate</i> , 2006, 66, 966-970. | 1.2 | 8 |
| 79 | Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. <i>Journal of Clinical Pathology</i> , 2006, 59, 984-987. | 1.0 | 27 |
| 80 | Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2006, 108, 3045-3045. | 0.6 | 13 |
| 81 | Favorable Influence of Rituximab with High Dose Sequential Chemotherapy (R-HDS) Programs and Autologous Stem Cell Transplantation (ASCT) in Salvage Treatment for Patients with Refractory or Relapsed B-Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2006, 108, 2744-2744. | 0.6 | 0 |
| 82 | Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: The Northern Italy Leukemia Group (NILG) Experience.. <i>Blood</i> , 2006, 108, 5380-5380. | 0.6 | 0 |
| 83 | Four Years Experience in Bladder Preserving Management for Muscle Invasive Bladder Cancer. <i>European Urology</i> , 2005, 47, 773-779. | 0.9 | 42 |
| 84 | Granulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adults. <i>The Cochrane Library</i> , 0, , . | 1.5 | 0 |